SRRK Scholar Rock (SRRK) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001727196
Form 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
186
13F, latest reported quarter
What the filings say about SRRK
Insiders, 180 days
+$11.1M net bought
1 buyer · 5 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$48.6K
1 notice
Scholar Rock insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Scholar Rock Holding Corp insiders bought a net $11.1M of stock across 169 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 17 earlier Form 4 trades (code P or S) here by this insider (14 buys, 3 sales), the last on Oct 23, 2026.
- +11.2% median (+30.6% mean) 90-day return after 4 previous buys.
- The trade is 0.8% of the 6,380,517 shares held after it.
- No other insider bought within 30 days.
- 186 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director AKKARAJU SRINIVAS bought about $2.0M of SRRK on Oct 26, 2026; 186 funds added in the latest 13F quarter.Context
- 17 earlier Form 4 trades (code P or S) here by this insider (14 buys, 3 sales), the last on Oct 23, 2026.
- +11.2% median (+30.6% mean) 90-day return after 4 previous buys.
- The trade is 13.6% of the 723,020 shares held after it.
- No other insider bought within 30 days.
- 186 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director AKKARAJU SRINIVAS bought about $4.1M of SRRK on Oct 26, 2026, the largest insider purchase at the company since 2025; 186 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (10 buys, 3 sales), the last on Oct 7, 2025.
- +11.2% median (+30.6% mean) 90-day return after 4 previous buys.
- The trade is 0.7% of the 6,331,029 shares held after it.
- No other insider bought within 30 days.
- 186 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director AKKARAJU SRINIVAS bought about $1.9M of SRRK on Oct 23, 2026, the largest insider purchase at the company since 2025; 186 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (10 buys, 3 sales), the last on Oct 7, 2025.
- +11.2% median (+30.6% mean) 90-day return after 4 previous buys.
- The trade is 15.1% of the 624,038 shares held after it.
- No other insider bought within 30 days.
- 186 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director AKKARAJU SRINIVAS bought about $3.9M of SRRK on Oct 23, 2026, the largest insider purchase at the company since 2025; 186 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (10 buys, 3 sales), the last on Oct 7, 2025.
- +11.2% median (+30.6% mean) 90-day return after 4 previous buys.
- The trade is 0.0% of the 6,331,529 shares held after it.
- No other insider bought within 30 days.
- 186 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director AKKARAJU SRINIVAS bought about $20.9K of SRRK on Oct 23, 2026, the largest insider purchase at the company since 2025; 186 funds added in the latest 13F quarter.169 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$11.1M over 180 days
+$12.0M over 90 days
more than 96% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
186 funds bought in last quarter
more than 88% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
21.3% of the float short (float per yahoo 2026-10-27) · 12.7 days to cover · settled 2026-10-15
more than 91% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 13 in the prior 90
Why it matters
The absence is the signal: 13 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Oct 27Director AKKARAJU SRINIVAS bought $12.0M (6 trades, Oct 23 to Oct 26)
Oct 1Director Katie Peng filed to sell $48.6K by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch SRRK
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+45.5%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SRRK: institutional holders (13F)
13F holdings, latest reported quarter
17,995,241 sh
$989.7M
9,575,013 sh
$526.6M
9,494,084 sh
$522.2M
6,897,652 sh
$379.4M
6,727,085 sh
$370.0M
Congress trades in SRRK
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SRRK planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Katie Peng
Filed 2026-10-01
$48.6K
Mohammed Qatanani
Filed 2026-07-06
$640.0K
Kristina Burow
Filed 2026-07-01
$167.3K
Jeffrey S. Flier
Filed 2026-07-01
$167.3K
Michael Gilman
Filed 2026-07-01
$139.4K
SRRK mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Eventide Gilead Fund
$80.3M position · as of 2026-06-30
2.3%
Eventide Healthcare & Life Sciences Fund
$34.8M position · as of 2026-06-30
1.9%
Select Biotechnology Portfolio
$81.4M position · as of 2026-05-31
1.5%
PGIM Jennison Health Sciences Fund
$17.4M position · as of 2026-05-29
1.3%
VOYA SMALLCAP OPPORTUNITIES PORTFOLIO
$2.6M position · as of 2026-06-30
1.2%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$124.2M position · as of 2026-06-30
1.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $11.1M bought by insiders over 180 days, 186 funds added last quarter, $48.6K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
SRRK financials
Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM SRRK
| FY Dec 2025 | n/a |
| FY Dec 2024 | $33.2M |
| FY Dec 2023 | $33.2M |
| FY Dec 2022 | $33.2M |
| FY Dec 2021 | $18.8M |
| Jun 2026 | $0 |
| Mar 2026 | $0 |
| Dec 2025 | $0 |
| Sep 2025 | $0 |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM SRRK
| FY Dec 2025 | n/a |
| FY Dec 2024 | -741.1% |
| FY Dec 2023 | -500.1% |
| FY Dec 2022 | -405.2% |
| FY Dec 2021 | -700.5% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$297.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM SRRK
| FY Dec 2025 | -$300.6M |
| FY Dec 2024 | -$201.0M |
| FY Dec 2023 | -$145.3M |
| FY Dec 2022 | -$133.8M |
| FY Dec 2021 | -$132.0M |
| Jun 2026 | -$70.3M |
| Mar 2026 | -$82.2M |
| Dec 2025 | -$75.5M |
| Sep 2025 | -$69.0M |
| Jun 2025 | -$77.2M |
| Mar 2025 | -$78.9M |
| Dec 2024 | -$49.5M |
| Sep 2024 | -$52.5M |
At each fiscal year end
Single quarter
Debt to equity
0.78x
long-term 2026-06-30 plus current 2024-06-30 (24 months older than the period end); equity 2026-06-30
Debt to equity SRRK
| FY Dec 2025 | 0.41x |
| FY Dec 2024 | 0.14x |
| FY Dec 2023 | 0.22x |
| FY Dec 2022 | 0.19x |
| FY Dec 2021 | 0.29x |
| Jun 2026 | 0.78x |
| Mar 2026 | 0.72x |
| Dec 2025 | 0.41x |
| Sep 2025 | 0.41x |
| Jun 2025 | 0.22x |
| Mar 2025 | 0.16x |
| Dec 2024 | 0.14x |
| Sep 2024 | 0.65x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-1.50x
TTM operating cash flow over long-term 2026-06-30 plus current 2024-06-30 (24 months older than the period end)
Cash flow to debt SRRK
| FY Dec 2025 | -2.96x |
| FY Dec 2024 | -3.88x |
| FY Dec 2023 | -2.90x |
| FY Dec 2022 | -2.63x |
| FY Dec 2021 | -2.54x |
| Jun 2026 | -1.50x |
| Mar 2026 | -1.53x |
| Dec 2025 | -2.96x |
| Sep 2025 | -2.71x |
| Jun 2025 | -5.02x |
| Mar 2025 | -4.48x |
| Dec 2024 | -3.88x |
| Sep 2024 | -3.65x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-167.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SRRK
| FY Dec 2025 | -123.1% |
| FY Dec 2024 | -82.8% |
| FY Dec 2023 | -68.4% |
| FY Dec 2022 | -62.2% |
| FY Dec 2021 | -60.9% |
| Jun 2026 | -167.8% |
| Mar 2026 | -139.0% |
| Dec 2025 | -123.1% |
| Sep 2025 | -217.9% |
| Jun 2025 | -171.9% |
| Mar 2025 | -106.6% |
| Dec 2024 | -82.8% |
| Sep 2024 | -183.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-94.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SRRK
| FY Dec 2025 | -86.0% |
| FY Dec 2024 | -62.6% |
| FY Dec 2023 | -49.6% |
| FY Dec 2022 | -40.6% |
| FY Dec 2021 | -38.1% |
| Jun 2026 | -94.6% |
| Mar 2026 | -86.7% |
| Dec 2025 | -86.0% |
| Sep 2025 | -119.5% |
| Jun 2025 | -111.3% |
| Mar 2025 | -78.2% |
| Dec 2024 | -62.6% |
| Sep 2024 | -105.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital SRRK
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-109.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SRRK
| FY Dec 2025 | -99.0% |
| FY Dec 2024 | -71.4% |
| FY Dec 2023 | -57.1% |
| FY Dec 2022 | -47.8% |
| FY Dec 2021 | -44.4% |
| Jun 2026 | -109.7% |
| Mar 2026 | -96.9% |
| Dec 2025 | -99.0% |
| Sep 2025 | -147.9% |
| Jun 2025 | -133.8% |
| Mar 2025 | -90.3% |
| Dec 2024 | -71.4% |
| Sep 2024 | -126.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing SRRK
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$4.8B
market value at close 2026-10-26 on 2026-08-03 shares, plus long-term 2026-06-30 plus current 2024-06-30 (24 months older than the period end), minus cash 2026-06-30
Enterprise value SRRK
| FY Dec 2025 | $4.3B |
| FY Dec 2024 | $3.9B |
| FY Dec 2023 | $1.3B |
| FY Dec 2022 | $414.8M |
| FY Dec 2021 | $709.3M |
| Jun 2026 | $6.4B |
| Mar 2026 | $5.4B |
| Dec 2025 | $4.3B |
| Sep 2025 | $3.4B |
| Jun 2025 | $3.3B |
| Mar 2025 | $3.0B |
| Dec 2024 | $3.9B |
| Sep 2024 | $616.4M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-5.8%
TTM free cash flow over market value at close 2026-10-26
FCF yield SRRK
| FY Dec 2025 | -6.7% |
| FY Dec 2024 | -5.0% |
| FY Dec 2023 | -10.7% |
| FY Dec 2022 | -28.6% |
| FY Dec 2021 | -15.1% |
| Jun 2026 | -4.5% |
| Mar 2026 | -5.4% |
| Dec 2025 | -6.7% |
| Sep 2025 | -7.7% |
| Jun 2025 | -7.7% |
| Mar 2025 | -7.6% |
| Dec 2024 | -5.0% |
| Sep 2024 | -29.5% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing SRRK
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $0 | n/a | n/a | $33.2M |
| Operating income | -$384.6M | -$252.1M | -$171.3M | -$134.4M |
| Net income | -$378.0M | -$246.0M | -$166.0M | -$134.5M |
| EPS (diluted) | -3.29 | -2.47 | -1.99 | -2.26 |
| Operating cash flow | -$300.0M | -$200.9M | -$145.2M | -$132.7M |
| Cash | $323.5M | $177.9M | $101.9M | $103.3M |
| Long-term debt | $99.7M | $50.1M | $48.7M | $49.7M |
SEC XBRL, fiscal years, as known on 2026-10-28
SRRK Stock Sonar score 6/7 axes
Find similar shapesCompareSRRK ranks highest on institutional and government (88th percentile) and insider conviction (76th), and lowest on growth (1st), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
SRRK filings, in plain words
Are Scholar Rock insiders buying or selling SRRK?
In the 180 days to 2026-10-28, Scholar Rock insiders were net buyers, a net $11.1M: $12.0M of purchases and $923.1K of sales reported on Form 4, by 1 buyer and 5 sellers.
Are there planned insider sales of SRRK?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $48.6K of stock; the latest, by Katie Peng, was filed 2026-10-01.
Read the full summary
In the 180 days to 2026-10-28, Scholar Rock insiders were net buyers of SRRK, a net $11.1M across purchases and sales reported on Form 4 by 1 buyer and 5 sellers. Purchases outweighed sales more than tenfold by value. None of the 13 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $48.6K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
